Form 144 Filed for Agilent: Insider Sale of 28,081 Shares on 08/29/2025

Rhea-AI Filing Summary

Agilent Technologies (A) Form 144 notice shows a proposed sale of 28,081 common shares via Fidelity Brokerage Services on the NYSE with an aggregate market value of $3,508,993.30. The filing lists two option-originated lots: 22,898 shares from an option granted 11/17/2020 and 5,183 shares from an option granted 11/22/2023, both indicated as to be sold on 08/29/2025 for cash. The filer reports 284,064,728 shares outstanding and no sales by the same person in the past three months. The notice contains the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Positive

• Full transparency via Rule 144 notice including option grant dates and lot sizes
• No prior sales by the same person in the past three months, reducing concerns about rapid insider unloading
• Seller represents no undisclosed material adverse information about the issuer

Negative

• Insider sale of 28,081 shares, which could be perceived negatively by some investors despite small size

Insights

Securities Analyst

TL;DR: Small insider option exercise sale relative to shares outstanding; routine Form 144 disclosure with limited market impact.

The proposed disposition of 28,081 shares equals roughly 0.01% of the 284.1 million shares outstanding, so the filing is unlikely to materially affect Agilent's market capitalization or liquidity. The shares derive from previously granted options (2020 and 2023) and are to be sold through a retail brokerage, suggesting a standard exercise-and-sell for cash rather than a block institutional divestiture. Absence of sales in the past three months and the seller's certification about material information further indicate a routine compliance filing.

Corporate Governance Specialist

TL;DR: Procedural insider sale notice consistent with option exercise; governance implications appear minimal.

Form 144 is a procedural requirement when an affiliate proposes a sale under Rule 144. The filing documents the origin of the shares from option grants and indicates cash payment upon sale, which aligns with typical option exercise practices. There is no disclosure here of a trading plan date or other governance signals such as accelerated insider divestiture, and the seller affirms no undisclosed material information. Overall, this is a compliance disclosure without governance red flags.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	28081	3508993.30	284064728	08/29/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/29/2025	Option Granted - 11/17/2020	Issuer			22898	08/29/2025	Cash
Common	08/29/2025	Option Granted - 11/22/2023	Issuer			5183	08/29/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Agilent's (A) Form 144 filing disclose?

The filing discloses a proposed sale of 28,081 common shares via Fidelity on the NYSE with aggregate value $3,508,993.30, from options granted in 2020 and 2023, to be sold on 08/29/2025.

How large is the proposed sale relative to Agilent's outstanding shares?

The sale of 28,081 shares represents about 0.01% of the 284,064,728 shares outstanding reported in the filing.

Did the filer report any sales in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

What is the origin of the shares being sold?

The shares come from option exercises: 22,898 shares from an option granted 11/17/2020 and 5,183 shares from an option granted 11/22/2023.

Is there any indication of undisclosed material information?

The filer signs the notice representing they do not know of any material adverse information about the issuer that has not been publicly disclosed.